NSE · WANBURY · Pharmaceuticals
Wanbury Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹166 Cr with net profit ₹3 Cr — a 1.96% net margin, versus 13.19% the period before.
Shareholding
As of 2026-09-30
- Promoter42.98%
- Public56.3%
- FII0.71%
- DII0%
20,432 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.22× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #58 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,21,587 Cr | 33.37 | 5.04 | 13.74% | 20.29% |
| Laurus Labs Limited | ₹1,17,729 Cr | 107.65 | 22.21 | 16.77% | 15.04% |
| Zydus Lifesciences Ltd. | ₹1,17,606 Cr | 24.09 | 4.34 | 18.59% | 16.09% |
| Dr Reddys Laboratories Ltd. | ₹1,10,578 Cr | 39.5 | 2.85 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,10,064 Cr | 35.44 | 3.11 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,02,510 Cr | 43.93 | 5.83 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹94,581 Cr | 25.02 | 2.5 | 9.25% | 10.7% |
| Lupin Limited | ₹89,789 Cr | 15.07 | 4 | 23.76% | 18.72% |
| Glenmark Pharmaceuticals Ltd. | ₹65,025 Cr | 20.83 | 6.19 | 28.08% | 10.22% |
| Alkem Laboratories Ltd. | ₹60,392 Cr | 26.5 | 4.37 | 16.66% | 14.31% |
| Wanbury Limited(this company) | ₹616 Cr | 14.34 | 7.95 | 51.51% | 6.83% |
AI analysis
AI-generated · google/gemini-2.5-flashWanbury Limited is listed on the Indian markets with a market capitalization of Rs 1161 Cr. The one-year high for the share price was Rs 358.85 and the one-year low was Rs 161.5.
Positives
- +Return on capital employed (ROCE) is 27.98%, indicating efficient use of capital.
- +Return on equity (ROE) is 20%, suggesting good profitability relative to shareholder investment.
Negatives
- −Promoter shareholding has 86.69% of shares pledged, which could be a risk.
- −The debt-to-equity ratio is 3.38, indicating a high reliance on debt financing.
- −Promoter holding decreased from 76.76% in June 2019 to 43.0161% in June 2026.
- −The stock is under ST-ASM · ASM 1 surveillance, which may indicate increased monitoring by regulators.
- −No quarterly results have been disclosed since June 2025.
Financial Performance
The company reported revenue of Rs 603.01 Cr. Annual revenue for March 2025 was Rs 172 Cr with a net profit of Rs 20.26 Cr. Quarterly revenue for June 2025 stood at Rs 163.18 Cr, generating a net profit of Rs 13.49 Cr.
Profitability & Returns
Wanbury Limited reported an EPS of Rs 9.32. The return on equity (ROE) is 20% and the return on capital employed (ROCE) is 27.98%. The trailing twelve-month P/E ratio is 25.18.
Balance Sheet
The company has a book value of Rs 16.26. The debt-to-equity ratio is 3.38, indicating a relatively high level of debt compared to equity.
Ownership & Pledges
As of June 2026, promoter holding is 43.0161%, with 86.69% of these shares pledged.
Regulatory & Surveillance
The stock is currently under ST-ASM · ASM 1 surveillance, with 'ST-ASM' listed as a measure.
Data as of — price: 2026-10-28 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.